{"success":true,"data":{"pressRelease":{"id":"18462","rtpr_id":"nPNAmnTdwa","ticker":"7733","exchange":"TSE Tokyo","all_tickers":["7733"],"title":"Olympus Signs Global Distribution Agreement with EndoRobotics, Adds Robot-Assisted Technologies to EndoTherapy Portfolio","author":"PR Newswire","published_at":"2026-05-04T07:00:00.986Z","article_body":"Olympus Signs Global Distribution Agreement with EndoRobotics, Adds\nRobot-Assisted Technologies to EndoTherapy Portfolio\nPR Newswire\n\nTOKYO, May 4, 2026\n\nPartnership Aimed at Expanding Patient Access to Advanced EndoTherapeutic\nProcedures\n\nTOKYO, May 4, 2026 /PRNewswire/ -- Olympus Corporation\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679411-1&h=2525525090&u=https%3A%2F%2Fwww.olympus-global.com%2F&a=Olympus+Corporation)\n(Olympus), a global MedTech company committed to advancing endoscopy-enabled\ncare, today announced it has signed an exclusive global distribution agreement\nwith EndoRobotics Co., Ltd. Under this agreement, robot-assisted technologies\nmanufactured by EndoRobotics will be distributed globally by Olympus\nexclusively as part of its EndoTherapy portfolio. \n\nThis collaboration will help drive broader adoption of advanced endoscopic\nprocedures —such as endoscopic submucosal dissection (ESD) — helping\nclinicians deliver organ-sparing, minimally invasive care with precision and\nconfidence.\n\nOlympus aims to expand patient access to endoscopic procedures for treatment\nof early-stage cancers and precancerous lesions of the GI tract. By removing\ndiseased tissue without resecting the organ, physicians performing ESD may\nallow for less procedural risk, fewer post-treatment complications and shorter\npatient recovery.(1,2) EndoRobotics technologies can enhance precision,\ncontrol and efficiency in complex procedures such as ESD. These technologies\nplay an increasingly important role in supporting consistent outcomes,\nparticularly as the global incidence of GI cancers continues to rise.(3) \n\nThe agreement reflects Olympus' approach to advancing endoluminal robotics,\nbringing new technologies that support complex endoscopic therapy to global\nmarkets today, while continuing to invest in longer-term platform innovations\ndesigned to further transform endoscopy-enabled care.\n\n\"We are pleased to have the opportunity to work with EndoRobotics to advance\ntherapeutic capabilities in GI patient care,\" said Mike Callaghan, General\nManager, EndoTherapy at Olympus. \"This collaboration supports our strategy to\nbroaden adoption of advanced treatment options such as ESD. By offering\nrobot-assisted technologies, we aim to help clinicians perform these complex\ntherapeutic procedures with greater confidence and efficiency, while\nmaintaining a strong focus on patient safety and optimizing outcomes.\"\n\n\"For years, EndoRobotics has focused on developing next-generation robotic\nsolutions for therapeutic endoscopy. Today, we are stepping into a much bigger\nmission,\" said Byung Gon Kim, co-CEO, and Daehie Hong, co-CEO of EndoRobotics,\nCo., LTD. \"Our goal is to help more patients around the world receive\ntreatment faster, recover sooner, and return to their families in better\nhealth. To achieve this, we are proud to partner with Olympus Corporation, a\nleading endoscopy company. Together, we aim to transform the global\ntherapeutic endoscopy market.\"\n\nLeveraging Olympus' global commercial infrastructure and EndoRobotics'\ndevelopment capabilities, the companies will bring these new endotherapeutic\nsolutions to global markets, beginning with the U.S., in an effort to help\nadvance the safe and effective practice of third-space endoscopy using\nrobot-assisted technologies.\n\nAdditional details regarding availability and regional product launches will\nbe shared in accordance with regulatory requirements and local market\nconsiderations.\n\nAbout Olympus \nAt Olympus, we are committed to Our Purpose of making people's lives\nhealthier, safer and more fulfilling. As a global medical technology company,\nwe partner with healthcare professionals to provide innovative solutions and\nservices for early detection, diagnosis and minimally invasive treatment,\naiming to improve patient outcomes by elevating the standard of care in\ntargeted disease states.\n\nFor more than 100 years, Olympus has pursued a goal of contributing to society\nby producing products designed with the purpose of delivering optimal outcomes\nfor its customers around the world. For more information, visit the Olympus\nwebsite\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679411-1&h=538015313&u=https%3A%2F%2Fwww.olympus-global.com%2F&a=Olympus+website)\nand follow the Olympus LinkedIn account\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679411-1&h=1325432915&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Folympus-corp%2F&a=Olympus+LinkedIn+account).\n\nAbout EndoRobotics \nENDOROBOTICS is a technology-driven company dedicated to advancing minimally\ninvasive treatments for gastrointestinal diseases through the development of\nnext-generation endoscopic intervention robotics. Navigating the complex and\nflexible structure of the human digestive system presents significant\ntechnical challenges; ENDOROBOTICS addresses these challenges through\nexpertise built on years of research. By leveraging  these robotic\ntechnologies, ENDOROBOTICS aims to improve procedural precision, minimize\npatient burden, and pioneer the future of minimally invasive gastrointestinal\ncare.\n\nAll trademarks, logos and brand names are the property of their respective\nowners.\n\n(1) Safi, M.H., Hui, Z., Xiaoyong, W. et al. Endoscopic submucosal\ndissection: a safe alternative to surgical intervention for young patients\nunder 45 years of age with early gastric cancer. ESD vs. surgery in young EGC\npatients. BMC Cancer 25, 1895 (2025).\nhttps://doi.org/10.1186/s12885-025-15293-4(2) Qian M, Sheng Y, Wu M, Wang S,\nZhang K. Comparison between Endoscopic Submucosal Dissection and Surgery in\nPatients with Early Gastric Cancer. Cancers. 2022; 14(15):3603.\nhttps://doi.org/10.3390/cancers14153603(3) Singh A. Global burden of five\nmajor types of gastrointestinal cancer. Prz Gastroenterol. 2024;19(3):236-254.\ndoi: 10.5114/pg.2024.141834.\n\nLogo - https://mma.prnewswire.com/media/1774929/Olympus_Logo.jpg\n\nView original\ncontent:https://www.prnewswire.com/apac/news-releases/olympus-signs-global-distribution-agreement-with-endorobotics-adds-robot-assisted-technologies-to-endotherapy-portfolio-302761007.html\n\nSOURCE Olympus Corporation\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/1774929/Olympus_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPNAmnTdwa","title":"Olympus Signs Global Distribution Agreement with EndoRobotics, Adds Robot-Assisted Technologies to EndoTherapy Portfolio","author":"PR Newswire","ticker":"7733","created":"2026-05-04T07:00:00.986Z","tickers":["7733"],"exchange":"TSE Tokyo","article_body":"Olympus Signs Global Distribution Agreement with EndoRobotics, Adds\nRobot-Assisted Technologies to EndoTherapy Portfolio\nPR Newswire\n\nTOKYO, May 4, 2026\n\nPartnership Aimed at Expanding Patient Access to Advanced EndoTherapeutic\nProcedures\n\nTOKYO, May 4, 2026 /PRNewswire/ -- Olympus Corporation\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679411-1&h=2525525090&u=https%3A%2F%2Fwww.olympus-global.com%2F&a=Olympus+Corporation)\n(Olympus), a global MedTech company committed to advancing endoscopy-enabled\ncare, today announced it has signed an exclusive global distribution agreement\nwith EndoRobotics Co., Ltd. Under this agreement, robot-assisted technologies\nmanufactured by EndoRobotics will be distributed globally by Olympus\nexclusively as part of its EndoTherapy portfolio. \n\nThis collaboration will help drive broader adoption of advanced endoscopic\nprocedures —such as endoscopic submucosal dissection (ESD) — helping\nclinicians deliver organ-sparing, minimally invasive care with precision and\nconfidence.\n\nOlympus aims to expand patient access to endoscopic procedures for treatment\nof early-stage cancers and precancerous lesions of the GI tract. By removing\ndiseased tissue without resecting the organ, physicians performing ESD may\nallow for less procedural risk, fewer post-treatment complications and shorter\npatient recovery.(1,2) EndoRobotics technologies can enhance precision,\ncontrol and efficiency in complex procedures such as ESD. These technologies\nplay an increasingly important role in supporting consistent outcomes,\nparticularly as the global incidence of GI cancers continues to rise.(3) \n\nThe agreement reflects Olympus' approach to advancing endoluminal robotics,\nbringing new technologies that support complex endoscopic therapy to global\nmarkets today, while continuing to invest in longer-term platform innovations\ndesigned to further transform endoscopy-enabled care.\n\n\"We are pleased to have the opportunity to work with EndoRobotics to advance\ntherapeutic capabilities in GI patient care,\" said Mike Callaghan, General\nManager, EndoTherapy at Olympus. \"This collaboration supports our strategy to\nbroaden adoption of advanced treatment options such as ESD. By offering\nrobot-assisted technologies, we aim to help clinicians perform these complex\ntherapeutic procedures with greater confidence and efficiency, while\nmaintaining a strong focus on patient safety and optimizing outcomes.\"\n\n\"For years, EndoRobotics has focused on developing next-generation robotic\nsolutions for therapeutic endoscopy. Today, we are stepping into a much bigger\nmission,\" said Byung Gon Kim, co-CEO, and Daehie Hong, co-CEO of EndoRobotics,\nCo., LTD. \"Our goal is to help more patients around the world receive\ntreatment faster, recover sooner, and return to their families in better\nhealth. To achieve this, we are proud to partner with Olympus Corporation, a\nleading endoscopy company. Together, we aim to transform the global\ntherapeutic endoscopy market.\"\n\nLeveraging Olympus' global commercial infrastructure and EndoRobotics'\ndevelopment capabilities, the companies will bring these new endotherapeutic\nsolutions to global markets, beginning with the U.S., in an effort to help\nadvance the safe and effective practice of third-space endoscopy using\nrobot-assisted technologies.\n\nAdditional details regarding availability and regional product launches will\nbe shared in accordance with regulatory requirements and local market\nconsiderations.\n\nAbout Olympus \nAt Olympus, we are committed to Our Purpose of making people's lives\nhealthier, safer and more fulfilling. As a global medical technology company,\nwe partner with healthcare professionals to provide innovative solutions and\nservices for early detection, diagnosis and minimally invasive treatment,\naiming to improve patient outcomes by elevating the standard of care in\ntargeted disease states.\n\nFor more than 100 years, Olympus has pursued a goal of contributing to society\nby producing products designed with the purpose of delivering optimal outcomes\nfor its customers around the world. For more information, visit the Olympus\nwebsite\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679411-1&h=538015313&u=https%3A%2F%2Fwww.olympus-global.com%2F&a=Olympus+website)\nand follow the Olympus LinkedIn account\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679411-1&h=1325432915&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Folympus-corp%2F&a=Olympus+LinkedIn+account).\n\nAbout EndoRobotics \nENDOROBOTICS is a technology-driven company dedicated to advancing minimally\ninvasive treatments for gastrointestinal diseases through the development of\nnext-generation endoscopic intervention robotics. Navigating the complex and\nflexible structure of the human digestive system presents significant\ntechnical challenges; ENDOROBOTICS addresses these challenges through\nexpertise built on years of research. By leveraging  these robotic\ntechnologies, ENDOROBOTICS aims to improve procedural precision, minimize\npatient burden, and pioneer the future of minimally invasive gastrointestinal\ncare.\n\nAll trademarks, logos and brand names are the property of their respective\nowners.\n\n(1) Safi, M.H., Hui, Z., Xiaoyong, W. et al. Endoscopic submucosal\ndissection: a safe alternative to surgical intervention for young patients\nunder 45 years of age with early gastric cancer. ESD vs. surgery in young EGC\npatients. BMC Cancer 25, 1895 (2025).\nhttps://doi.org/10.1186/s12885-025-15293-4(2) Qian M, Sheng Y, Wu M, Wang S,\nZhang K. Comparison between Endoscopic Submucosal Dissection and Surgery in\nPatients with Early Gastric Cancer. Cancers. 2022; 14(15):3603.\nhttps://doi.org/10.3390/cancers14153603(3) Singh A. Global burden of five\nmajor types of gastrointestinal cancer. Prz Gastroenterol. 2024;19(3):236-254.\ndoi: 10.5114/pg.2024.141834.\n\nLogo - https://mma.prnewswire.com/media/1774929/Olympus_Logo.jpg\n\nView original\ncontent:https://www.prnewswire.com/apac/news-releases/olympus-signs-global-distribution-agreement-with-endorobotics-adds-robot-assisted-technologies-to-endotherapy-portfolio-302761007.html\n\nSOURCE Olympus Corporation\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/1774929/Olympus_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-04T07:00:01.037501623Z","server_sent_at_ms":1777878001037},"received_at":"2026-05-04T07:00:01.102Z","source_url":null},"analysis":{"id":"13338","press_release_id":"18462","analysis_json":{"industry":{"label":"Health Care Equipment & Services","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Olympus Corporation signed an exclusive global distribution agreement with EndoRobotics to integrate robot-assisted technologies into its EndoTherapy portfolio.\n\nThe partnership is designed to expand patient access to advanced procedures like endoscopic submucosal dissection (ESD), which offer organ-sparing treatment for early-stage GI cancers.\n\nLeveraging Olympus' global commercial infrastructure, the companies will begin introducing these solutions in the U.S. market, with further regional launches to follow.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Olympus bolsters its endoscopy suite with an exclusive global deal for EndoRobotics' robotic technologies."},"keyFigures":{},"quotedText":"We are pleased to have the opportunity to work with EndoRobotics to advance therapeutic capabilities in GI patient care","namedEntities":{"people":[{"name":"Mike Callaghan","role":"General Manager, EndoTherapy at Olympus"},{"name":"Byung Gon Kim","role":"co-CEO of EndoRobotics"},{"name":"Daehie Hong","role":"co-CEO of EndoRobotics"}],"products":["robot-assisted technologies","EndoTherapy portfolio"],"companies":[{"name":"Olympus Corporation","ticker":"7733"},{"name":"EndoRobotics Co., Ltd.","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Exclusive global distribution agreement meaningfully expands the company's EndoTherapy portfolio into robot-assisted technologies, a high-growth area for treating GI cancers. However, the lack of disclosed financial terms or specific revenue guidance limits the immediate materiality score."},"tickerRelevance":{"others":[],"primary":"7733"},"globalImportance":35,"audienceRelevance":30,"eventTypeSecondary":["product_launch"],"importanceComponents":{"tickerTier":"large-cap-medtech","eventGravity":"strategic-commercial-partnership","sectorWeight":"health-care"}},"event_type":"partnership","event_type_secondary":["product_launch"],"sentiment":"bullish","material_impact_score":3,"narrative":"Olympus Corporation signed an exclusive global distribution agreement with EndoRobotics to integrate robot-assisted technologies into its EndoTherapy portfolio.\n\nThe partnership is designed to expand patient access to advanced procedures like endoscopic submucosal dissection (ESD), which offer organ-sparing treatment for early-stage GI cancers.\n\nLeveraging Olympus' global commercial infrastructure, the companies will begin introducing these solutions in the U.S. market, with further regional launches to follow.","key_figures":{},"named_entities":{"people":[{"name":"Mike Callaghan","role":"General Manager, EndoTherapy at Olympus"},{"name":"Byung Gon Kim","role":"co-CEO of EndoRobotics"},{"name":"Daehie Hong","role":"co-CEO of EndoRobotics"}],"products":["robot-assisted technologies","EndoTherapy portfolio"],"companies":[{"name":"Olympus Corporation","ticker":"7733"},{"name":"EndoRobotics Co., Ltd.","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T07:01:11.520Z","global_importance":35,"audience_relevance":30,"importance_components":{"tickerTier":"large-cap-medtech","eventGravity":"strategic-commercial-partnership","sectorWeight":"health-care"}},"durationMs":69688,"modelName":"glm-4.7"}}